Unapproved research chemicalNo human evidence

5-Amino-1MQ

Also referred to as 5-Amino-1-methylquinolinium

Entirely preclinical. No published human efficacy or safety trials.

Molecule class: Small-molecule NNMT inhibitor (not a peptide)
Category: Metabolic
Last evidence review: 2026-08-23

Compare this compound Check interactions Solution calculator

Human studies

Animal / in vitro

Graded claims

—

Participants

Mechanism

What is being studied

Inhibits nicotinamide N-methyltransferase, proposed to influence adipocyte metabolism and cellular NAD+ availability.

Evidence

Claims, graded individually

Each statement below carries its own evidence level, its own confidence rating, and its own account of what remains unestablished. A compound does not have a single grade.

Metabolic & Body-Composition Research

DPreclinicalLow confidenceNo human evidence

5-Amino-1MQ has been reported to reduce adipose mass in mouse models.

What is not established

No human trials of any kind exist in the published record.

Supporting sources (1)

Animal studyAnimalIdentifier pending verification

5-Amino-1MQ as an NNMT inhibitor in metabolic models

Multiple · Biochemistry and metabolism literature · 2018

Population: Mouse models of diet-induced obesity
Endpoint: Adipose mass, NNMT activity, metabolic markers
Route: Oral and intraperitoneal in animal models
Quantity as reported: mg/kg in animal models — not translatable
Frequency: Daily in the models

Result. Reported reduction in adipose mass in the mouse models studied.

Adverse events. Not characterised in humans.

Limitations. Entirely preclinical. No published human efficacy or safety trials.

Search PubMed for this literature →

Last evidence review: 2026-08-23

Human evidence

0 human studies catalogued

Human and non-human evidence are kept strictly separate. They are never pooled, averaged, or presented as a single body of support.

No human evidence on file

No adequate human study for this compound is catalogued. This is an absence of data. It is neither a finding of safety nor a finding of harm, and it means nothing published supports directional statements about human effect.

Preclinical evidence

Animal and in-vitro research

Kept separate deliberately. Most preclinical findings do not translate to humans, and animal quantities expressed per kilogram do not convert to human quantities by simple arithmetic.

Animal studyAnimalIdentifier pending verification

5-Amino-1MQ as an NNMT inhibitor in metabolic models

Multiple · Biochemistry and metabolism literature · 2018

Population: Mouse models of diet-induced obesity
Endpoint: Adipose mass, NNMT activity, metabolic markers
Route: Oral and intraperitoneal in animal models
Quantity as reported: mg/kg in animal models — not translatable
Frequency: Daily in the models

Result. Reported reduction in adipose mass in the mouse models studied.

Adverse events. Not characterised in humans.

Limitations. Entirely preclinical. No published human efficacy or safety trials.

Search PubMed for this literature →

Pharmacology

Reported parameters

Half-life

Not characterised

Human pharmacokinetics are not published.

Routes studied

Oral (animal)
Intraperitoneal (animal)

Evidence from one route does not transfer to another. Topical, oral, and injected administration can produce entirely different exposure from the same quantity.

Regulatory status

Not approved for human use.

Storage as documented

No approved labelling exists.

Safety

Signals reported in the literature

This lists what has been reported. It is not a complete safety profile, and for several compounds in this catalogue no systematic safety surveillance exists at all.

No human safety data exist

Limitations

What the evidence cannot tell you

Given as much prominence as the findings, because for most compounds in this category it is the more important half.

No human trials of any kind in the published record
Animal mg/kg quantities do not translate

Reference

Evidence grading key

AStrong

Multiple high-quality human trials, or strong systematic-review or meta-analytic evidence.

BModerate

Human controlled evidence exists, but replication or sample size is limited.

CPreliminary

Small human studies, observational evidence, or early-phase clinical work.

DPreclinical

Predominantly animal or in-vitro evidence. No adequate human outcome data.

EMechanistic

Biological plausibility or mechanistic reasoning without adequate outcome evidence.

XInsufficient / conflicting

Evidence is absent, irreconcilable, or too weak to support any directional statement.

Other compounds studied in the same research areas

Semaglutide

A long-acting GLP-1 receptor agonist. Among the most extensively studied compounds in this catalogue, with large randomised trials and regulatory approval for specific indications.

Tirzepatide

A dual incretin receptor agonist with large randomised evidence including a 176-week readout that also reported post-withdrawal weight regain.

Retatrutide

An investigational triple agonist with a published phase 2 trial. It is not approved, and phase 3 outcome data are not established.

Cagrilintide

An investigational amylin analogue studied alone and in combination with semaglutide. Combination programme readouts continue to evolve.